FLOT3

Brief title: FLOT3
Design: Prospective study with 5-FU, Leucovirin, Oxaliplatin and Docetaxel (FLOT) in patients with locally advanced, limited metastatic or extensive adenocarcinoma of the stomach or esophagogastric junction
No of patients: 250
Status: Completed

Patients with locally advanced or metastatic gastric carcinoma or carcinoma of the esophagogastric junction without prior palliative therapy will be treatedin this multicentre phase II study. Primary outcome measure was overall survival, secondary outcome measures were quality of life, pregression free survival and rate of R0-resections, rate of pathological remissions and perioperative morbidity and mortality in stratum A and B

LKP:
Prof. Dr. S.E. Al-Batran
Institut für Klinisch-Onkologische Forschung
Krankenhaus Nordwest GmbH
Steinbacher Hohl 2-26
60488 Frankfurt/Main

More information